

Most people living with type 2 diabetes also have MASLD

MASLD is defined by presence of:




Hepatic steatosis

≥1 cardiometabolic risk factor*


MASH
Metabolic dysfunction-associated steatohepatitis (severe form of MASLD)

*As the nomenclature update is recent (June 2023), all data shown were of patients defined with the former NAFLD/NASH definitions. 98% of patients in a European NAFLD registry fulfill the new MASLD criteria.*Pre-diabetes or diabetes, overweight or obesity, hypertension, dyslipidemia.

Algorithm for diagnosis of steatotic liver disease



Overview of screening for advanced liver fibrosis and MASLD management



Provided is an example of a FIB-4 calculator that may be used in clinical practice. Diabetes Canada does not endorse any specific tool, and clinicians should use their judgment when selecting resources.



Diabetes Canada Recommendations on MASLD 2025

